Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia

N/ACompletedNCT01520246

Children's Oncology Group20 enrolled

Overview

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in samples from patients with T-cell acute lymphoblastic leukemia.

OBJECTIVES: * To test whether the tumor suppressor candidate gene PDLIM2 is downregulated in human cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and to use the human T-lymphotropic virus 1 (HTLV-1)-mediated in vitro transformation of human T cells as control. OUTLINE: Previously collected cancer and control tissues are analyzed for the expression patterns of PDLIM2 and other control genes. Human T-cells isolated from human blood are also co-cultured with HTLV-1-transformed T-cell lines.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia Lymphoma

Interventions

gene expression analysisGENETIC

laboratory biomarker analysisOTHER

Eligibility

Sex: ALLMax age: 120 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Specimens (e.g., tissue, blood, and bodily fluids) of various cancer cells and or tissues from de-identified patients such as T-cell acute lymphoblastic leukemia (T-ALL) * Normal control tissue PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Outcomes

Primary Outcomes

PDLIM2 expression patterns in cancer and control tissues

8-week survival of human T-cell co-cultured with HTLV-1-transformed T-cell lines

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.